Combination of anti‐PD‐L1 antibody with peptide MEL‐dKLA targeting M2 tumor‐associated macrophages suppresses breast cancer metastasis
Open Access
- 16 February 2022
- journal article
- letter
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 42 (4) , 345-349
Abstract
Click on the article title to read more.Keywords
Funding Information
- National Research Foundation of Korea (NRF‐2020R1A2B5B03002164)
- National Research Foundation of Korea (NRF‐2020R1A2B5B03002164)
This publication has 10 references indexed in Scilit:
- Delivery Strategies for Melittin-Based Cancer TherapyACS Applied Materials & Interfaces, 2021
- CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast CancerInternational Journal of Molecular Sciences, 2020
- The Roles of CD8+ T Cell Subsets in Antitumor ImmunityTrends in Cell Biology, 2020
- Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogelTheranostics, 2020
- Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptideJournal for ImmunoTherapy of Cancer, 2019
- Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 proteinJournal of Hematology & Oncology, 2017
- CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophagesJournal of Experimental Medicine, 2015
- Breast Cancer Subtypes Predispose the Site of Distant MetastasesAmerican Journal of Clinical Pathology, 2015
- Macrophages in Tumor Microenvironments and the Progression of TumorsJournal of Immunology Research, 2012
- Risk Factors for Initial Lung Metastasis from Breast Invasive Ductal Carcinoma in Stages I-III of Operable PatientsJapanese Journal of Clinical Oncology, 2008